Literature DB >> 31732375

Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.

Christopher W Baugh1, Michael Levine2, David Cornutt3, Jason W Wilson4, Richard Kwun5, Charles E Mahan6, Charles V Pollack7, Evie G Marcolini8, Truman J Milling9, W Frank Peacock10, Rachel P Rosovsky11, Fred Wu12, Ravi Sarode13, Alex C Spyropoulos14, Todd C Villines15, Timothy D Woods16, John McManus17, James Williams18.   

Abstract

Bleeding is the most common complication of anticoagulant use. The evaluation and management of the bleeding patient is a core competency of emergency medicine. As the prevalence of patients receiving anticoagulant agents and variety of anticoagulants with different mechanisms of action, pharmacokinetics, indications, and corresponding reversal agents increase, physicians and other clinicians working in the emergency department require a current and nuanced understanding of how best to assess, treat, and reverse anticoagulated patients. In this project, we convened an expert panel to create a consensus decision tree and framework for assessment of the bleeding patient receiving an anticoagulant, as well as use of anticoagulant reversal or coagulation factor replacement, and to address controversies and gaps relevant to this topic. To support decision tree interpretation, the panel also reached agreement on key definitions of life-threatening bleeding, bleeding at a critical site, and emergency surgery or urgent invasive procedure. To reach consensus recommendations, we used a structured literature review and a modified Delphi technique by an expert panel of academic and community physicians with training in emergency medicine, cardiology, hematology, internal medicine/thrombology, pharmacology, toxicology, transfusion medicine and hemostasis, neurology, and surgery, and by other key stakeholder groups.
Copyright © 2019 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31732375      PMCID: PMC7393606          DOI: 10.1016/j.annemergmed.2019.09.001

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  61 in total

1.  Coagulopathic hemorrhage with use of synthetic cannabinoids.

Authors:  Isaac Boyack; Oleg Opsha
Journal:  Am J Emerg Med       Date:  2018-10-16       Impact factor: 2.469

Review 2.  Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?

Authors:  Stacy A Voils; Brian Baird
Journal:  Thromb Res       Date:  2012-11-06       Impact factor: 3.944

3.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

4.  US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014.

Authors:  Nadine Shehab; Maribeth C Lovegrove; Andrew I Geller; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz
Journal:  JAMA       Date:  2016-11-22       Impact factor: 56.272

5.  Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban.

Authors:  Yuko Honda; Taketoshi Furugohri; Yoshiyuki Morishima
Journal:  Pharmacology       Date:  2017-11-03       Impact factor: 2.547

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

7.  Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

Authors:  John W Eikelboom; Shamir R Mehta; Sonia S Anand; Changchun Xie; Keith A A Fox; Salim Yusuf
Journal:  Circulation       Date:  2006-08-14       Impact factor: 29.690

8.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

9.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

Authors:  M Irem Baharoglu; Charlotte Cordonnier; Rustam Al-Shahi Salman; Koen de Gans; Maria M Koopman; Anneke Brand; Charles B Majoie; Ludo F Beenen; Henk A Marquering; Marinus Vermeulen; Paul J Nederkoorn; Rob J de Haan; Yvo B Roos
Journal:  Lancet       Date:  2016-05-10       Impact factor: 79.321

10.  The impact of early outcome events on the effect of tranexamic acid in post-partum haemorrhage: an exploratory subgroup analysis of the WOMAN trial.

Authors:  Amy Brenner; Haleema Shakur-Still; Rizwana Chaudhri; Bukola Fawole; Sabaratnam Arulkumaran; Ian Roberts
Journal:  BMC Pregnancy Childbirth       Date:  2018-06-07       Impact factor: 3.007

View more
  7 in total

1.  Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.

Authors:  Olivia S Costa; Stuart J Connolly; Mukul Sharma; Jan Beyer-Westendorf; Mary J Christoph; Belinda Lovelace; Craig I Coleman
Journal:  Crit Care       Date:  2022-06-16       Impact factor: 19.334

Review 2.  Major publications in the critical care pharmacotherapy literature: 2019.

Authors:  Melanie Smith Condeni; Alyson T Basting; Patrick G Costello; Ashley DePriest; Evert A Eriksson; Heather Evans; Kristie Hertel; Andre L Holder; Alyssa N Kester; Kinsey R Kowalski; Carolyn Magee Bell; Barbara McLean; Michael Reichert; Melissa Santibañez; Patrick M Wieruszewski; Andrea Sikora Newsome
Journal:  J Crit Care       Date:  2020-12-27       Impact factor: 3.425

3.  Reply to "Key Points to Consider When Evaluating Andexxa for Formulary Addition".

Authors:  Charles E Mahan
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

4.  Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.

Authors:  Megan A Rech; Dalila Masic; Drayton A Hammond
Journal:  West J Emerg Med       Date:  2021-02-26

Review 5.  Management of Coagulopathy in Bleeding Patients.

Authors:  Stefan Hofer; Christoph J Schlimp; Sebastian Casu; Elisavet Grouzi
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

6.  Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.

Authors:  Alexander T Cohen; Megan Lewis; Augusta Connor; Stuart J Connolly; Patrick Yue; John Curnutte; Raza Alikhan; Peter MacCallum; Joachim Tan; Laura Green
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-03-05

7.  Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study.

Authors:  Anne E Merrelaar; Magdalena S Bögl; Nina Buchtele; Marieke Merrelaar; Harald Herkner; Christian Schoergenhofer; Job Harenberg; Jonathan Douxfils; Romain Siriez; Bernd Jilma; Alexander O Spiel; Michael Schwameis
Journal:  Thromb Haemost       Date:  2022-07-04       Impact factor: 6.681

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.